Tag - QNRX

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.